Monitor upcoming FDA meeting and potential BLA submission timeline, as the positive PFS data could support accelerated approval despite the OS crossover issue.
Price Chart
Executive Summary
Compass Therapeutics announced positive Phase 2/3 trial data for tovecimig in biliary tract cancer, showing statistically significant improvements in overall response rate and progression-free survival, though overall survival was not met due to high crossover. The company plans to meet with the FDA for a potential Biologics License Application.
Key Facts
- Tovecimig combination achieved 17.1% ORR vs 5.3% for paclitaxel alone (p=0.031)
- Statistically significant improvement in median PFS: 4.7 months vs 2.6 months (HR=0.44, p<0.0001)
- OS endpoint not met due to 54% crossover rate from control arm
- Crossover patients showed significantly improved median OS of 12.8 months vs 6.1 months for non-crossover patients
- Tovecimig was generally well tolerated with no new safety signals
Financial Impact
Potential for accelerated approval pathway and future commercialization
Risk Factors
- FDA may require additional data beyond PFS for approval
- High crossover rate complicates overall survival interpretation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-002720 |
| Exhibit: exh_992.htm | 0001171843-26-002720 |
| Exhibit: exh_991.htm | 0001171843-26-002720 |
| Document: 0001171843-26-002720-index-headers.html | 0001171843-26-002720 |
| Document: 0001171843-26-002720-index.html | 0001171843-26-002720 |
| Document: 0001171843-26-002720.txt | 0001171843-26-002720 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 3d ago | Press Release | $0.7472 | awaiting T+20 | — | $0.7474 (+0.03%) |
Sep 22, 2026 5w ago | 8-K | $1.24 $0.8330 | ▲ +32.82% | ▲ +32.26% | $0.7474 (+39.73%) |
Aug 21, 2026 9w ago | Institutional Cluster | $2.40 $1.90 | ▼ −20.83% | ▼ −20.55% | $0.7474 (−68.86%) |
Aug 6, 2026 11w ago | 8-K | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | $0.7474 (−62.44%) |
Aug 6, 2026 11w ago | Press Release | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | $0.7474 (−62.44%) |
Jul 17, 2026 14w ago | Press Release | $2.05 $2.25 | ▲ +9.76% | ▲ +5.31% | $0.7474 (−63.54%) |
Jul 1, 2026 16w ago | 8-K | $2.27 $1.94 | ▼ −14.54% | ▼ −14.12% | $0.7474 (−67.07%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.03 $2.33 | ▲ +14.78% | ▲ +13.00% | $0.7474 (−63.18%) |
May 21, 2026 22w ago | Press Release | $2.07 $2.09 | ▲ +0.72% | ▲ +2.14% | $0.7474 (−63.89%) |
May 5, 2026 25w ago | 8-K | $1.95 $2.08 | ▲ +6.67% | ▲ +1.71% | $0.7474 (−61.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers